LAUSR

BAFF inhibition in SLE—Is tolerance restored?

Sign Up to like & get
recommendations!
1 Published in 2019 at "Immunological Reviews"

DOI: 10.1111/imr.12810

Abstract: The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares and organ damage. BAFF and its… read more here.

Keywords: inhibition sle; baff april; inhibition; baff inhibition ... See more keywords